Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ANAnnovis Bio, Inc. logo

Annovis Bio, Inc. (ANVS)

New York Stock Exchange · Currency in USD
$1.00 ▲ +0.01 (+0.77%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.00 ▲ +0.00 (+0.07%)
After hours: Oct 23, 7:51 PM ET

Summary

Previous Close
$0.99
Open
$1.00
Day's Range
$0.96 – $1.01
52 Week Range
$0.95 – $5.50
Volume
315,786
Avg. Volume
869,459
Market Cap
$42.65M
Beta (5Y Monthly)
1.23
PE Ratio (TTM)
--
EPS (TTM)
-$1.32
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$25.67

Profile: Annovis Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
7
CEO
Maria L. Maccecchini

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.30
DateEst.Actual
Aug 14, 2026-$0.45-$0.40Beat
May 15, 2026-$0.40-$0.63Miss
Mar 16, 2026-$0.31-$0.39Miss
Nov 12, 2025-$0.36-$0.37Miss
Aug 12, 2025-$0.36-$0.32Beat
May 13, 2025-$0.47-$0.32Beat

Analyst view

Consensus price target
$25.67 ▲ +2,468.8%
Range $21.00 – $30.00
Rating: Buy
Buy 78% · Hold 22% · Sell -0%

Get free alerts on ANVS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.